Skip to main content

Information updates

RACP Foundation Research Awards

Applications are now open for the RACP Foundation Research Awards, which provide research funding for 2026.
Up to 50 awards with a total value of around $2.5 million are available to RACP Fellows and Advanced Trainees from Australia and Aotearoa New Zealand

Career Development Fellowships – close Monday 30 June 2025
Research Establishment Fellowships -  close Tuesday 8 July 2025
Research Entry Scholarships (PhD) – close Tuesday 15 July 2025

Full details of all awards offered and previous recipients are available on the website

Continue reading

National Allergy Council projects allocated to ASCIA - May 2025 update

The National Allergy Council is a partnership between the Australasian Society of Clinical Immunology and Allergy (ASCIA) and Allergy & Anaphylaxis Australia (A&AA), funded by the Australian Government Department of Health and Aged Care to implement the National Allergy Strategy. As partners in the National Allergy Council, we work together to improve the lives of 5 million Australians with allergic conditions by:

  • Developing accessible, consistent and evidence-based resources
  • Improving awareness and knowledge through resources and support
  • Promoting resources, support and quality allergy healthcare services

We work with patients, carers, community, health professionals and the health system to make a positive impact on the management of allergic conditions.

ASCIA’s main role in the National Allergy Council s to improve education, training and resources as part of the following projects:

  • Schools/Childcare - for schools, children’s education/care services and the community.
  • Shared Care for Allergy – for health professionals
  • Drug (Medication) Allergy - for health professionals.

The following is a summary of main achievements, and projects yet to be completed.

National Allergy Council Schools/Childcare project - achievements for activities allocated to ASCIA in 2024-2025:

  • Development of a new ASCIA training website https://training.ascia.org.au/, updating of ASCIA's learning management system (LMS) and updating of course content to enhance the user experience, improve access and increase use of ASCIA anaphylaxis e-training courses for schools, children’s education/care and community.  
  • Development of a new ASCIA Anaphylaxis Training Refresher Video www.allergy.org.au/ascia-videos for schools, children's education/care and community, based on feedback from course participants and the content of ASCIA anaphylaxis refresher e-training courses. 
  • Increased promotion of ASCIA anaphylaxis online training for schools, children’s education/care and community, through the ASCIA website, e-newsletters, distribution of brochures and social media,  resulting in 110,216 course completions in 2024, an increase of 23% compared to 2023.
  • Evaluation reports www.allergy.org.au/ascia-reports#nacscec based on feedback surveys (completed by 43,945 users in 2023 and 5,254 users in 2022) from ASCIA anaphylaxis e-training courses for schools, children's education/care and community. 
  • Ongoing maintenance and support of ASCIA anaphylaxis e-training courses for schools, children's education/care with 2,119 help requests received and resolved in 2023 and 1,058 help requests received and resolved from January to June 2024.

The following activities are due for completion in 2025-2026:

  • Evaluation reports based on 110,216 feedback surveys from 2024 ASCIA anaphylaxis e-training course completions  for schools, children's education/care and community. 
  • Development of a scoping report for pre-qualification/undergraduate education/training for people studying to work in schools and children's education/care. (Due March 2025).

National Allergy Council Shared Care for Allergy project - achievements for activities allocated to ASCIA in 2024-2025: 

  • ASCIA submitted a new application to the Medical Services Advisory Committee (MSAC) for a Medical Benefits Schedule (MBS) item number for supervised oral food challenges (OFC) on 27 March 2025 (due date was 28 March 2025).
  • Progress reports received for 5 health professional education and training initiatives www.allergy.org.au/national-allergy-strategy selected for funding through an EOI process. 
  • Development of a new ASCIA training website https://traininghp.ascia.org.au/, updating of ASCIA's learning management system (LMS) and updating of anaphylaxis course content to enhance the user experience, improve access and increase use of ASCIA anaphylaxis and allergy e-training courses for health professionals. 
  • Accreditation of ASCIA anaphylaxis e-training for health professionals (2025 version) by the
    • Australian Primary Health Care Nurses Association (APNA)
    • Australian College of Rural and Remote Medicine (ACRRM)
    • Pharmaceutical Society of Australia (PSA) 
    • Royal Australian College of General Practitioners (RACGP) 
    .
  • Increased promotion of ASCIA anaphylaxis e-training courses for health professionals through the ASCIA website, e-newsletters, social media and medical events, resulting in 14,011  course completions in 2024, an increase of 150% compared to 2023.
  • Evaluation reports www.allergy.org.au/ascia-reports#scap based on 14,011  feedback surveys from 2024 ASCIA anaphylaxis and allergy e-training course completions for health professionals, which represents a 150% increase in course completions compared to 2023. 
  • Increased promotion of ASCIA resources through the ASCIA website, e-newsletters and social media, with a reach of more than 12,000  followers/subscribers each month and more than 3 million website pageviews each year (~250,000 each month).
  • Increased promotion of ASCIA resources through participation in 12 medical events throughout Australia (including Healthed conferences and webcasts) with a total of more than 14,000 delegates www.allergy.org.au/ascia-reports#sca, to promote ASCIA education, training and clinical resources. 
  • Promotion of patient/carer organisations by updating of more than 100 ASCIA patient/carer educational resources www.allergy.org.au/patients including changes to improve readability. 
  • Development and promotion of ASCIA Quicklinks www.allergy.org.au/about-ascia/quick-links to improved access to more than 400 ASCIA online education, training and clinical resources.
  • Application submitted for MBS food challenge item numberwww.allergy.org.au/about-ascia/info-updates/ascia-application-for-mbs-item-for-supervised-oral-food-challenges
  • Initiating the development of an ASCIA referral toolkit www.allergy.org.au/patients/allergy-and-clinical-immunology-services to address issues relating to the process of referring patients to and from allergy services. 
  • Ongoing maintenance and support for ASCIA e-training courses for health professionals.

The following activities are due for completion in 2025:

  • Promotion of patient/carer organisations by updating of all ASCIA health professional resources. https://www.allergy.org.au/hp/ 
  • Development of a scoping report for pre-qualification/undergraduate education/training for people studying to work as health professionals. (Due March 2025).
  • Development of an ASCIA referral toolkit www.allergy.org.au/patients/allergy-and-clinical-immunology-services to address issues relating to the process of referring patients to and from allergy services. 
  • Updating of the ASCIA Food Allergy Course for Dietitians to include online webcasts and in-person case-based learning to be held during the ASCIA Annual Conference week. 

National Allergy Council Drug (Medication) Allergy project 

The following activities are due for completion in 2025:

  • Development of a new ASCIA drug (medication) allergy etraining course for health professionals.
  • Development of other ASCIA drug (medication) allergy resources, including penicillin antibiotic allergy delabeling guidelines and drug allergy terminology, working in collaboration with the National Allergy Council.
  • An application to MSAC for an MBS item number for drug challenges.

Visit the Australian Government Department of Health and Aged Care website to learn how the National Allergy Council (a partnership between ASCIA and Allergy & Anaphylaxis Australia) collaborate with the National Allergy Centre of Excellence (NACE).

The National Allergy Council works together with NACE to help improve allergy care and research in Australia. Allergic diseases are one of the country’s major public health challenges. The collaboration is supported by funding from the Australian Government.

Continue reading

ASCIA anaphylaxis e-training approved by APNA, ACCRM, PSA and RACGP

ASCIA online courses provide accessible, consistent and evidence-based training in anaphylaxis, allergy and immune deficiencies. The updated 2025 version of ASCIA anaphylaxis e-training for health professionals has been approved as a CPD activity by the following professional organisations:

  • Australian Primary Health Care Nurses Association (APNA)
  • Australian College of Rural and Remote Medicine (ACRRM)
  • Pharmaceutical Society of Australia (PSA) 
  • Royal Australian College of General Practitioners (RACGP) 
ASCIA Online Training Updates 2025

To enhance the user experience, improve access and increase usage, in 2025 ASCIA etraining courses have been:

It is important that ASCIA e-training courses are regularly reviewed and updated, as the usage continues to increase since they were first introduced in 2010. 

ASCIA Online Training Completions 

ASCIA anaphylaxis and allergy e-training courses were completed by a total of 124,227 course participants in 2024, a 32% increase compared with 94,193 in 2023, including:

  • 87,580 school anaphylaxis course completions - an increase of 19% compared to 74,201 course completions in 2023*
  • 14,318 children's education/care (CEC) anaphylaxis course completions - an increase of 57% compared to 9,133 course completions in 2023
  • 14,011 health professional anaphylaxis and allergy course completions - an increase of 150% compared to 5,589 course completions in 2023**
  • 4,621 schools, CEC and community anaphylaxis refresher course completions - an increase of 30% compared to 3,568 course completions in 2023 
  • 2,816 first aid (community) anaphylaxis course completions - an increase of 12% compared to 2,514 course completions in 2023 

*Course completions in 2024 are in addition to completions of ASCIA anaphylaxis e-training courses licenced to be on NSW, QLD and WA Education Departments for use on their LMS platforms. 

**The significant increase in course completions is largely due to the increased promotion of the courses by ASCIA. The increase suggests that there is a high need for health professionals to have access to this form of training, reflecting the rising prevalence of allergic disease in Australia and New Zealand. 

The mandatory evaluation reports for 2024 indicate that ASCIA anaphylaxis and allergy courses for health professionals were completed by:

  • 5,622 nurses (including nurse practitioners and nurse assistants)
  • 3,132 pharmacists
  • 543 pharmacy assistants
  • 259 general practitioners
  • 108 dietitians
  • 97 paediatricians
  • 95 medical/health educators
  • 81 paramedics
  • 3,278 other health professionals

In 2024, ASCIA courses were also completed by 796 students who are not yet working as health professionals. 

Each ASCIA e-training course includes mandatory evaluation surveys which provide feedback about preference regarding online training. Future ASCIA course updates will be based on this feedback, which includes information relevant to undergraduate and postgraduate anaphylaxis and allergy training.

Continue reading

ASCIA 2025 Conference registration and abstract submission

The ASCIA 2025 Conference is being held from Tuesday 2 to Friday 5 September 2025 at the Brisbane Convention and Exhibition Centre. This is a hybrid conference, which enables virtual registration for delegates who cannot attend in-person. On-demand viewing of recorded sessions will be available for all registered delegates for six months after the conference, resulting in further CPD opportunities. 

The program features current allergy, clinical immunology and immunopathology issues and research presented by more than 60 speakers, including 5 international experts.

To view the Program Book, register and submit abstracts go to https://ascia2025.com/

Earlybird registration and abstract submissions close on Thursday 3 July 2025.

The ASCIA Food Allergy Course for Dietitians (in-person only) will be held as part of the ASCIA 2025 Conference on Friday 5 September 2025, 08.15-17.00. Dietitians can register for this in-person course on Friday only, or register for the full conference (including the Allergy Update for Dietitians on Thursday 4 September) and opt for the Dietitians Course on Friday. Participants will be sent a link to online learning that needs to be completed prior to the course.

Other events being held during the ASCIA 2025 Conference week include:

  • Mental Health Training for Allergy Health Professionals Workshop(in-person only) on Monday 1 September 2025, 11.00-17.00 at Rydges South Bank, Brisbane. Register at https://www.trybooking.com/DBNMT
  • Clinical Immunogenomics Research Consortium Australasia (CIRCA) Symposiumon Monday 1 September 2025. Registration will open soon.

Continue reading

National Allergy Priorities for Research

 

What's involved?

  • Complete the short, anonymous, online survey before 5pm 30 June.  
  • Enter for a chance to WIN a copy of The Allergy Friendly Family Cookbook
  • Provide your email address if you want to learn about the second stage of SNAPR, where you could vote on the top allergy research priorities.

Who can take part?

Adults living in Australia who:

  • Have, or had, allergies
  • Care for someone with allergies
  • Treat people with allergies.

Before you get started

  • If you have allergies or care for someone with allergies, take a moment to think about the areas of future allergy research that matter most to you. These might be prevention, diagnosis, triggers, treatment or day-to-day concerns.
  • If you are involved in allergy services or policy, we also value your thoughts on what you consider to be important areas for future allergy research.

Continue reading

EOIs for 2025 AIFA grant round are due 30 May   

It is a pleasure to announce that Expressions of Interest (EOIs) are invited from ASCIA members for AIFA grants that support clinically important research into allergy and other immune diseases.

EOIs are due by midnight on 30 May 2025 and the form is on the AIFA website www.allergyimmunology.org.au/grants

Early Career and New Researcher Grants

2 x $10,000 AIFA Viatris Early Career and New Researcher Grants – Allergy

2 x $10,000 AIFA Early Career and New Researcher Grants – PID/Autoimmunity

These grants encourage new research projects in allergy, immunology or autoimmunity which do not yet have major funding. Eligible Chief Investigators are:

  • Early career scientist researchers working up to 5 years after completion of their PhD.
  • New researchers who are scientists, clinician researchers (such as advanced allergy/immunology trainees), or other health professionals.

Food Allergy Research Grants

$15,000 AIFA Professor Ann Kupa Food Allergy Research Grant

$15,000 AIFA DBV Technologies Food Allergy Research Grant

A full grant application will be due by 4th July for selected EOIs. AIFA grant recipients will be announced at the Gala Dinner of the ASCIA 2025 Conference in Brisbane on 4th September. The successful Chief Investigators will be informed two weeks before the event and will receive a complimentary invitation to the dinner.

Thank you to our generous supporters of 2025 AIFA grants

By 2027, AIFA’s goal is to award a cumulative total of $1 million in research grants, selected by experts, for clinically important research into allergy and other immune diseases. All donations directly fund research grants, and are tax deductible. Donate at www.allergyimmunology.org.au/donate

Continue reading

ASCIA Immunodeficiency Strategy - April 2025 update

To coincide with World PI Week (22 - 29 April 2025) and World Immunology Day on 29 April 2025, ASCIA is proud to announce that a new ASCIA Project Officer, Vargha Khosh Aein, has been appointed, to progress implementation of the ASCIA Immunodeficiency Strategy for Australia and New Zealand.  Whilst World PI Week is an annual event, this new role will ensure that ASCIA can progress the Strategy all year round. 

Since 2019 the Australasian Society for Clinical Immunology and Allergy (ASCIA) has been working together with patient/carer organisations and other stakeholders to develop the ASCIA Immunodeficiency Strategy at a national level for both Australia and New Zealand (the Strategy).  

The aim of the Strategy is to improve the health and wellbeing of people living with inborn errors of immunity (IEI) including hereditary angioedema (HAE) and other primary immune deficiency (PID) disorders, and minimise the burden on individuals, carers, health services and the community. 

In 2022 the Strategy was launched (virtually) to coincide with the International Day of Immunology (29 April) and World PID Week.

In 2023 an in-person implementation meeting was held in April,  where several priorities were identified.

In 2024 the following two Strategy priorities were achieved: 

ASCIA Immunodeficiency Strategy sponsorship opportunities

In 2025 ASCIA is seeking financial support to assist with further implementation of the Strategy to achieve most of the following ASCIA Immunodeficiency Strategy Goals over the next 3-5 years:

  1. Enable early diagnosis of severe combined immunodeficiency (SCID) by newborn screening

  2. Enable early diagnosis of other PID/IEI disorders through recognition of early warning signs of PID/IEI disorders, appropriate testing and treatment.

  3. Improve access to expert genetic diagnosis by using genomic and immune testing for patients with suspected or recently diagnosed PID/IEI disorders, or people with a family history of PID/IEI.

  4. Ensure equitable access to specialist and multi-disciplinary care for patients with PID/IEI disorders, including those living in regional, rural and remote areas.

  5. Ensure equitable access to treatments, that are appropriately supported and funded for patients with PID/IEI disorders.

  6. Increase support for PID/IEI education and training for patients, carers and health professionals.

  7. Increase support for multi-disciplinary clinical and laboratory PID/IEI research and collaborations.

  8. Ensure that the priorities of Indigenous Australian and Maori populations are represented in PID/IEI diagnosis, care and research.

What are the priorities for the ASCIA Immunodeficiency Strategy?

As a result of the Strategy meeting in April 2023, a list of priorities was developed which are outlined below,

Priority 1) Clinical Care Standard which includes care by GPs and other health professionals. (Goals 2, 3, 4, 5, 8)

Action completed:

Priority 2) ASCIA Working Parties will develop genetic testing and newborn screening (NBS) information to facilitate clinical implementation. (Goals 1, 2, 3, 8)

ASCIA will further address issues for better access and funding of genetic testing and the implementation of the clinical aspects for severe combined immunodeficiency (SCID) newborn screening (NBS). Whilst SCID NBS laboratory testing is now available in all jurisdictions in Australia and New Zealand, each region has differences which need to be considered in a consistent approach for SCID NBS and genetic testing.

Actions completed:

Further actions required:

  • ASCIA will provide a letter of support for an MSAC submission regarding genetic testing.
  • ASCIA will develop a new genetic testing guide for clinical immunology/allergy specialists.

Priority 3) Education Program for Transition from Paediatric to Adult Care and advocacy for resourcing of improved transition services based on the Clinical Care Standard (Goal 4, 6)

It has been recognised that there are many aspects of transitioning from paediatric to adult services that should be improved for complex patients with IEI and their families  Programs addressing education and support for patients, families and service providers and advocacy for funding of appropriate supportive multidisclinary resources utilising the ASCIA Clinical Care Standard will help address this.

Action completed:

  • The new ASCIA IEI Clinical Care Standard includes information about transitioning from paediatric to adult medical services. 

Further actions required:

  • Increased PID/IEI education and training resources developed for patients, carers and health professionals.

Priority 4) Advocacy, including discussions regarding Chronic Disease Strategy, patient/carer support organisations, health economics, barriers to access and Indigenous Australian/Maori involving clinicians and patients. (Goals 4, 5, 8). Advocacy will be central to many of our goals. The ASCIA Clinical Care Standard will be important, as will be collaborations with patient/carer support organisations and potential utilisation of the Chronic Disease Strategy.

Actions completed:

Priority 5) Research Initiatives, including an audit of access to testing/care and rejuvenation of ASCIA IEI Registry. (Goal 7)

An audit of access to testing and access to care was recommended, to better understand the inequities identified and the differences between access in public versus private heathcare systems.

Ways to rejuvenate the ASCIA IEI Registry are being considered, to optimise the entry of data, with recognition of the need for project officer support and the need to change from the existing waiver of consent to a formal consent process. An active ASCIA IEI Registry will allow documentation of numbers for advocacy and also allow expansion of research.

Actions completed:

  • Agreement by the ASCIA Board to develop a new ASCIA IEI Registry using REDCap (Research Electronic Data Capture), a secure web application for building and managing online databases. 

Further actions required:

  • ASCIA will develop a governance structure and draft data fields for a new ASCIA IEI Registry.
  • ASCIA will survey members regarding access to care/testing.
Why was the ASCIA Immunodeficiency Strategy initiated?

The ASCIA Immunodeficiency Strategy for Australia and New Zealand was established to address the needs of patients and their families affected by immunodeficiency in a targeted collaborative way. The development of the Strategy was built on the experience from the successful implementation of the National Allergy Strategy.

The first ASCIA Immunodeficiency Strategy meeting was held on Friday 8 March 2019 and was attended by a wide range of stakeholders including clinicians, patient/carer organisations and researchers. Despite the disruptions of the COVID pandemic over the last three years, there has been significant progress in some of these areas, but there are still substantial issues that need to be addressed.

The ASCIA Immunodeficiency Strategy for Australia and New Zealand document was developed from 2019-2021 and launched in April 2022. The Strategy includes eight goals to address key issues, as listed below. 

For more information about the Strategy visit https://nationalimmunodeficiencystrategy.org.au/

Continue reading

New international consensus report on anaphylaxis

A new international consensus report on anaphylaxis has been released by the Global Allergy and Asthma Excellence Network (GA2LEN) and published open access online in the Journal of Allergy and Clinical Immunology

The report was developed by an international panel of 46 leading medical experts from 14 countries (including ASCIA members from Australia) and patient advocacy organizations. The aim was to standardise definitions of anaphylaxis and teach people how to recognize and manage the condition.

Information in the report is consistent with ASCIA anaphylaxis resources which are available on the ASCIA website.

Key highlights of the report include:

  1. Unified Definition: The report introduces a new, widely agreed upon definition of anaphylaxis, emphasizing its potential to cause death and detailing the involved organ systems. This definition is designed to be easily understood by healthcare professionals and the general public to promote improved awareness of anaphylaxis.
  2. Educational Overview: An innovative educational tool for healthcare professionals from different medical fields, training backgrounds, and experience levels. The overview provides essential information on recognizing and managing anaphylaxis, including common causes, symptoms, timely treatment with adrenaline (epinephrine), and key concepts for managing life-threatening reactions.
  3. Clinical Support Tool: A new clinical support tool will help health professionals diagnose and treat anaphylaxis. This tool includes updated clinical criteria, indications, and dosing for intramuscular adrenaline and common findings from the different anaphylaxis organ systems. It is the first tool to include distinct infant findings to improve anaphylaxis management in young children.

 

This news item was issued on 9 April 2025 by Jill Smith, CEO of ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand. 

More Articles …